Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 10:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 46 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Neuromuscular blocking agents Clear all
Recruiting Not applicable Interventional

Limiting Emergence Phenomena After General Anesthesia With Combined LMA and ETT Airway Management Technique

NCT02708836
View directory record Official record
Conditions
Limit Emergence Phenomena After General Anesthesia
Interventions
Induction of anesthesia, Placement of LMA [Ambu (R) AuraGain (TM) disposable laryngeal mask], Laryngoscopy and placement of ETT, Ventilation via the ETT, Removal of the ETT, Intubation of the trachea through the LMA, Ventilation via the LMA, Emergence from anesthesia
Procedure · Device
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 22, 2026, 10:19 AM EDT
Completed Not applicable Interventional Results available

Thumb vs Great Toe Recovery

NCT04312256
View directory record Official record
Conditions
Residual Neuromuscular Blockade
Interventions
TetraGraph
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 4, 2024 · Synced Oct 22, 2026, 10:19 AM EDT
Active, not recruiting Phase 2 Interventional

Trial of Therapeutic Hypothermia in Patients With ARDS

NCT04545424
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult
Interventions
Hypothermia, Neuromuscular Blocking Agents, Standard of care
Device · Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 85 Years
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
19
States / cities
Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 22, 2026, 10:19 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Effect of Opioid Free Anesthetic on Post-Operative Opioid Consumption After Laparoscopic Bariatric Surgery

NCT04081545
View directory record Official record
Conditions
Opioid Use, Unspecified, Bariatric Surgery Candidate, Anesthesia
Interventions
Opioid Anesthetics, Non Opioid Analgesics
Drug
Lead sponsor
Christine Oryhan
Other
Eligibility
18 Years and older
Enrollment
181 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Oct 22, 2026, 10:19 AM EDT
Completed Phase 4 Interventional Results available

Safety of Sugammadex for the Reversal of Neuromuscular Blockade in American Society of Anesthesiologists (ASA) Class 3 or 4 Participants (MK-8616-145)

NCT03346057
View directory record Official record
Conditions
Reversal of Neuromuscular Blockade
Interventions
Sugammadex 2 mg/kg, Sugammadex 4 mg/kg, Sugammadex 16 mg/kg, Neostigmine + Glycopyrrolate, Rocuronium, Vecuronium
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
20
States / cities
Birmingham, Alabama • Tucson, Arizona • Loma Linda, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 22, 2026, 10:19 AM EDT
Completed Not applicable Interventional Results available

Electromyographic and Acceleromyographic Monitoring in Restricted Arm Movement Surgical Setting

NCT04352140
View directory record Official record
Conditions
Residual Neuromuscular Blockade
Interventions
Tetragraph, ToFscan
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 17, 2023 · Synced Oct 22, 2026, 10:19 AM EDT
Completed Not applicable Interventional Results available

Visual and Electromyography Assessments in Response to Train-of-Four Stimulation of the Ulnar Nerve

NCT04352127
View directory record Official record
Conditions
Residual Neuromuscular Blockade
Interventions
TetraGraph
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 10, 2022 · Synced Oct 22, 2026, 10:19 AM EDT
Completed Phase 4 Interventional Results available

Efficacy, Safety, and Pharmacokinetics of Sugammadex for Reversal of Neuromuscular Blockade (NMB) in Pediatric Participants (MK-8616-089)

NCT03351608
View directory record Official record
Conditions
Neuromuscular Blockade
Interventions
Sugammadex 2 mg/kg, Sugammadex 4 mg/kg, Neostigmine + Glycopyrrolate, Neostigmine + Atropine
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
2 Years to 16 Years
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
11
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2021 · Synced Oct 22, 2026, 10:19 AM EDT
Completed Phase 3 Interventional Results available

The POUR (Postoperative Urinary Retention) Study

NCT05276804
View directory record Official record
Conditions
Postoperative Urinary Retention
Interventions
Sugammadex
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 9, 2025 · Synced Oct 22, 2026, 10:19 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Validation of the REPS Prediction Tool

NCT03585400
View directory record Official record
Conditions
Residual Neuromuscular Blockade, Curarization, Postoperative Residual, Postoperative Respiratory Complication
Interventions
Observational Study
Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
101,510 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Oct 22, 2026, 10:19 AM EDT
Completed Not applicable Interventional Results available

Optimal Dose of Succinylcholine and Rocuronium for Electroconvulsive Therapy (ECT)

NCT01441960
View directory record Official record
Conditions
Neuromuscular Blockade, ECT
Interventions
Succinylcholine, Rocuronium
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 2, 2015 · Synced Oct 22, 2026, 10:19 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

NMBA Reversal and Postoperative Urinary Retention

NCT06948409
View directory record Official record
Conditions
Neuromuscular Blocking Agents, Urinary Retention After Procedure, Urinary Retention Postoperative, Neuromuscular Blockade Reversal Agent, Neuromuscular Blockade, Costs, Atropine, Sugammadex, Glycopyrrolate, Neostigmine, Anesthesia
Interventions
Choice of reversal agent (sugammadex or neostigmine [with muscaranic antagonist])
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
70,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 22, 2026, 10:19 AM EDT
Completed Phase 4 Interventional

The Early Reversibility of Rocuronium After Different Doses of Neostigmine

NCT00001520
View directory record Official record
Conditions
Paralysis
Interventions
neostigmine
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 22, 2026, 10:19 AM EDT
Completed Phase 4 Interventional Results available

Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616) for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to <2 Years (MK-8616-169)

NCT03909165
View directory record Official record
Conditions
Neuromuscular Blockade
Interventions
Sugammadex 2 mg/kg, Sugammadex 4 mg/kg, Neostigmine + Glycopyrrolate, Neostigmine + Atropine
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
1 Day to 2 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
7
States / cities
Palo Alto, California • Miami, Florida • Oklahoma City, Oklahoma + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2025 · Synced Oct 22, 2026, 10:19 AM EDT
Recruiting No phase listed Observational

Median Versus Ulnar Nerve Quantitative Electromyography Neuromuscular Blockade Monitoring Comparison

NCT06553131
View directory record Official record
Conditions
Neuromuscular Blockade
Interventions
Neuromuscular Transmission Monitoring
Device
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Oct 22, 2026, 10:19 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Phase I Clinical Trial to Evaluate the Safety, Pharmacokinetics and Efficacy of CW002

NCT01338935
View directory record Official record
Conditions
Healthy
Interventions
CW 002
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 49 Years
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 4, 2014 · Synced Oct 22, 2026, 10:19 AM EDT
Completed Not applicable Interventional Results available

An Anesthesia-Centered Bundle to Reduce Postoperative Pulmonary Complications: The PRIME-AIR Study

NCT04108130
View directory record Official record
Conditions
Postoperative Pulmonary Complications
Interventions
Preoperative Education, Intraoperative PEEP (Positive End-Expiratory Pressure) Individualization, Individualization of Neuromuscular Blockade, Postoperative Incentive Spirometry, Postoperative Ambulation
Other · Procedure · Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
794 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
16
States / cities
San Francisco, California • Stanford, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Oct 22, 2026, 10:19 AM EDT
Completed Not applicable Interventional

Does Residual Muscular Weakness Lead to an Increase in Respiratory Complications in Bariatric Patients?

NCT02037516
View directory record Official record
Conditions
Respiratory Complication, Morbid Obesity
Interventions
Accelomyography, Neostigmine, Qualitative Monitor
Device · Drug
Lead sponsor
Coastal Anesthesiology Consultants
Other
Eligibility
Not listed
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Saint Augustine, Florida
Source: ClinicalTrials.gov public record
Updated Feb 5, 2016 · Synced Oct 22, 2026, 10:19 AM EDT
Completed Phase 4 Interventional Results available

Comparison of Obturator Nerve Blockade and Neuromuscular Blockade

NCT03063255
View directory record Official record
Conditions
Cancer of Bladder
Interventions
Obturator block, Neuromuscular block
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 24, 2021 · Synced Oct 22, 2026, 10:19 AM EDT
Completed Not applicable Interventional

Does the Use of a Moisture Chamber Decrease the Incidence of Corneal Abrasions in Critically Ill Pediatric Patients?

NCT00129077
View directory record Official record
Conditions
Eye Injuries, Critically Ill
Interventions
plastic wrap over eye & lubrication applied q6 hrs
Procedure
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
2 Weeks to 17 Years
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
2
States / cities
Chicago, Illinois • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 10, 2007 · Synced Oct 22, 2026, 10:19 AM EDT
Not listed No phase listed Observational

Predictors of Upper Airway Function and Sleep-disordered Breathing in the Critically Ill

NCT02112604
View directory record Official record
Conditions
Critically Ill, Obstructive Sleep Apnea
Interventions
Ventilator, Alice PDx, Pulmonary function test, Muscle strength tests, Grip strength measurement, Sedatives and muscle relaxants given in the ICU
Device · Other · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 17, 2016 · Synced Oct 22, 2026, 10:19 AM EDT
Recruiting Not applicable Interventional

NMT EasyFit Sensor and Cable

NCT07394140
View directory record Official record
Conditions
Neuromuscular Blockade Monitoring, NMT
Interventions
Collection of NMT Technology
Device
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 22, 2026, 10:19 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Comparison of Two Quantitative EMG Monitors for Deep Neuromuscular Block in Laparoscopic/Robotic and VATS Surgery

NCT07706504
View directory record Official record
Conditions
Neuromuscular Blockade
Interventions
TetraGraph (Senzime)-Guided Neuromuscular Monitoring (Dominant Hand), TwitchView (Blink)-Guided Neuromuscular Monitoring (Dominant Hand)
Device
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 22, 2026, 10:19 AM EDT
Completed Phase 4 Interventional Results available

Sugammadex vs Placebo to Prevent Residual Neuromuscular Block

NCT02728726
View directory record Official record
Conditions
General Surgery
Interventions
Sugammadex, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 100 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
Jacksonville, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 14, 2022 · Synced Oct 22, 2026, 10:19 AM EDT